PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.